To treat pelvic nodes or not: could the greater testicular scatter dose from whole pelvic fields confound results of prostate cancer trials?

Journal of Clinical Oncology

Volumn 27, Issue 36, 2009, Pages 6076-6078

  King, Christopher R ^a   Kapp, Daniel S ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RADIOTHERAPY; CLINICAL TRIAL; HUMAN; LYMPH NODE METASTASIS; NOTE; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION SCATTERING; TREATMENT PLANNING; ARTICLE; LYMPH NODE; MALE; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PELVIS; PROSTATE TUMOR; RADIATION EXPOSURE; TESTIS;

CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; LYMPH NODES; MALE; PELVIS; PROSTATIC NEOPLASMS; TESTIS;

EID: 74949109801     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.24.3808     Document Type: Note

References (15)

1. Roach M 3rd, DeSilvio M, Lawton C, et al: Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: RTOG 9413. J Clin Oncol 21:1904-1911, 2003
2. Lawton CA, DeSilvio M, Roach M 3rd, et al: An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: Updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 69:646-655, 2007
3. Pommier P, Chabaud S, Lagrange JL, et al: Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 25:5366-5373, 2007
4. Boehmer D, Badakhashi H, Kuschke W, et al: Testicular dose in prostate cancer radiotherapy. Strahlenther Onkol 181:179-184, 2005
5. Amies CJ, Mameghan H, Rose A, et al: Testicular doses in definitive radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 32:839-846, 1995
6. Zagars GK, Pollack A: Serum testosterone levels after external beam radiation for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 39:85-89, 1997
7. Hermann RM, Henkel K, Christiansen H, et al: Testicular dose and hormonal changes after radiotherapy of rectal cancer. Radiother Oncol 75:83-88, 2005
8. Dueland S, Guren MG, Olsen DR, et al: Radiation therapy induced changes in male sex hormone levels in rectal cancer patients. Radiother Oncol 68:249-253, 2003
9. Pickles T, Graham P, Members of the British Columbia Cancer Agency Prostate Cohort Outcomes Initiative: What happens to testosterone after prostate radiation monotherapy and does it matter? J Urol 167:2448-2452, 2002
10. Bruheim K, Svartberg J, Carlsen E, et al: Radiotherapy for rectal cancer is associated with reduced serum testosterone and increased FSH and LH. Int J Radiat Oncol Biol Phys 70:722-727, 2008
11. Daniell HW, Clark JC, Pereira SE, et al: Hypogonadism following prostatebed radiation therapy for prostate carcinoma. Cancer 91:1889-1895, 2001
12. Roach M III, DeSilvio M, Valicenti R, et al: Whole-pelvis, mini-pelvis, or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the RTOG 9413 trial. Int J Radiat Oncol Biol Phys 66:647-653, 2006
13. Bruchovsky N, Klotz L, Crook J, et al: Locally advanced prostate cancer: Biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of PSA recurrence after radiotherapy. Cancer 109:858-867, 2007
14. Taussky D, Bae K, Bahary JP, et al: Does timing of androgen deprivation influence radiation-induced toxicity? A secondary analysis of RTOG protocol 9413. Urology 72:1125-1129, 2008
15. Shahidi M, Norman AR, Gadd J, et al: Recovery of serum testosterone, LH and FSH levels following neoadjuvant hormone cytoreduction and radical radiotherapy in localized prostate cancer. Clin Oncol 13:291-295, 2001